NVO - Novo Nordisk A/S

Novo Nordisk A/S

Novo Alle
Bagsvaerd 2880
Denmark
45 44 44 88 88
http://www.novonordisk.com

Sector: Healthcare
Industry: Biotechnology
Full-time employees: 42,158

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Lars Fruergaard Jørgensen	Pres & CEO	N/A	N/A	1966
Mr. Karsten Munk Knudsen	Exec. VP & CFO	N/A	N/A	1971
Dr. Mads Krogsgaard Thomsen	Exec. VP & Chief Science Officer	N/A	N/A	1960
Mr. Henrik Ehlers Wulff	Exec. VP and Head of Product Supply, Quality & IT	N/A	N/A	1970
Ms. Camilla Sylvest	Exec. VP and Head of Commercial Strategy & Corp. Affairs	N/A	N/A	1972

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. It also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases; and Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for liver-related cardio-metabolic diseases. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Corporate governance

Novo Nordisk A/S’s ISS governance QualityScore as of 4 October 2019 is 5. The pillar scores are Audit: 1; Board: 3; Shareholder rights: 10; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.